Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors.

Abstract

Pancreatic neuroendocrine tumors (PanNETs) represent a clinically challenging disease because these tumors vary in clinical presentation, natural history, and prognosis. Novel prognostic biomarkers are needed to improve patient stratification and treatment options. Several putative prognostic and/or predictive biomarkers (eg, alternative lengthening of telomeres, alpha-thalassemia/mental retardation, X-linked (ATRX)/Death Domain Associated Protein (DAXX) loss) have been independently validated. Additionally, recent transcriptomic and epigenetic studies focusing on endocrine differentiation have identified PanNET subtypes that display similarities to either α-cells or β-cells and differ in clinical outcomes. Thus, future prospective studies that incorporate genomic and epigenetic biomarkers are warranted and have translational potential for individualized therapeutic and surveillance strategies.

• Authors: Wenzel M Hackeng, Hussein A Assi, Florine H M Westerbeke, Lodewijk A A Brosens, Christopher M Heaphy
• Journal: Surgical pathology clinics (Surg Pathol Clin) Vol. 15 Issue 3 Pg. 541-554 (Sep 2022) ISSN: 1875-9157 [Electronic] United States
• PMID: 36049835 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2022 Elsevier Inc. All rights reserved.

Chemical References

• Adaptor Proteins, Signal Transducing
• Biomarkers
• Co-Repressor Proteins
• Molecular Chaperones
• Nuclear Proteins
• X-linked Nuclear Protein

Topics

• Adaptor Proteins, Signal Transducing (genetics)
• Biomarkers
• Co-Repressor Proteins (genetics)
• Humans
• In Situ Hybridization, Fluorescence
• Molecular Chaperones (genetics)
• Neuroendocrine Tumors (diagnosis, genetics, pathology)
• Nuclear Proteins (genetics)
• Pancreatic Neoplasms (diagnosis, genetics, pathology)
• Prognosis
• Prospective Studies
• X-linked Nuclear Protein (genetics)